ArticlePloS one2013
Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Discovery of natural products that modulate signaling in patient-derived cells.RSC chemical biology · 2026Article
- Copper (II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells.Oncology reports · 2023Article
- Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.Journal of ovarian research · 2019Article
- Multiplex Label Free Characterization of Cancer Cell Lines Using Surface Plasmon Resonance Imaging.Biosensors · 2019Article
- Review
- Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice.Molecular imaging and biology · 2017Article
- Profiling protein expression in circulating tumour cells using microfluidic western blotting.Nature communications · 2017Observational
- Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes.Oncotarget · 2015Article
- Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.Stem cells (Dayton, Ohio) · 2015Article
- Genetic barcoding with fluorescent proteins for multiplexed applications.Journal of visualized experiments : JoVE · 2015Article
- Flow cytometry protocols for surface and intracellular antigen analyses of neural cell types.Journal of visualized experiments : JoVE · 2014Article
- Cell surface antigen profiling using a novel type of antibody array immobilised to plasma ion-implanted polycarbonate.Cellular and molecular life sciences : CMLS · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Colon cancer is a deadly disease affecting millions of people worldwide. Current treatment challenges include management of disease burden as well as improvements in detection and targeting of tumor cells. To identify disease state-specific surface antigen signatures, we combined fluorescent cell barcoding with high-throughput flow cytometric profiling of primary and metastatic colon cancer lines (SW480, SW620, and HCT116). Our multiplexed technique offers improvements over conventional methods by permitting the simultaneous and rapid screening of cancer cells with reduced effort and cost. The method uses a protein-level analysis with commercially available antibodies on live cells with intact epitopes to detect potential tumor-specific targets that can be further investigated for their clinical utility. Multiplexed antibody arrays can easily be applied to other tumor types or pathologies for discovery-based approaches to target identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.